NASDAQ:PRTC PureTech Health (PRTC) Stock Price, News & Analysis → This could mean the end of the U.S dollar… (From Colonial Metals) (Ad) Free PRTC Stock Alerts $29.50 0.00 (0.00%) (As of 05/22/2024 ET) Add Compare Share Share Today's Range$29.50▼$29.5050-Day Range$24.67▼$30.9152-Week Range$17.08▼$34.00Volume62 shsAverage Volume676 shsMarket Capitalization$797.68 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get PureTech Health alerts: Email Address PureTech Health MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.02% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.26Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.73) to ($5.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.08 out of 5 starsMedical Sector916th out of 920 stocksPharmaceutical Preparations Industry423rd out of 424 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for PureTech Health.Read more about PureTech Health's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.02% of the outstanding shares of PureTech Health have been sold short.Short Interest Ratio / Days to CoverPureTech Health has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PureTech Health has recently increased by 3.92%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPureTech Health does not currently pay a dividend.Dividend GrowthPureTech Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRTC. Previous Next 2.4 News and Social Media Coverage News SentimentPureTech Health has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for PureTech Health this week, compared to 1 article on an average week.Search Interest2 people have searched for PRTC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PureTech Health insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.30% of the stock of PureTech Health is held by insiders.Percentage Held by InstitutionsOnly 0.04% of the stock of PureTech Health is held by institutions.Read more about PureTech Health's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for PureTech Health are expected to decrease in the coming year, from ($2.73) to ($5.17) per share.Price to Book Value per Share RatioPureTech Health has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about PureTech Health's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.” About PureTech Health Stock (NASDAQ:PRTC)PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Read More PRTC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRTC Stock News HeadlinesMay 23 at 7:00 AM | businesswire.comPureTech to Present at the Jefferies Global Healthcare ConferenceMay 21 at 7:05 AM | businesswire.comPureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile InfectionMay 20 at 2:25 AM | finanznachrichten.dePureTech Health plc: PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary ShareMay 20 at 2:00 AM | businesswire.comPureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary ShareApril 27, 2024 | seekingalpha.comPureTech Health plc (PRTC) Q4 2023 Earnings Call TranscriptApril 25, 2024 | finance.yahoo.comPureTech Announces Annual Results for Year Ended December 31, 2023April 18, 2024 | businesswire.comPureTech Health: Notice of ResultsApril 16, 2024 | finance.yahoo.comPureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary FibrosisApril 11, 2024 | lse.co.ukUS FDA hands fast track to PureTech head and neck cancer treatmentApril 11, 2024 | markets.businessinsider.comPureTech's LYT-200 Receives FDA Fast Track Designation For Treatment Of Head & Neck CancersApril 11, 2024 | businesswire.comPureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck CancersApril 9, 2024 | businesswire.comPureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management TransitionsMarch 18, 2024 | businesswire.comBristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 BillionMarch 13, 2024 | finance.yahoo.comPureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid LeukemiaFebruary 28, 2024 | finance.yahoo.comAKLI Mar 2024 3.000 callFebruary 27, 2024 | lse.co.ukPureTech notes positive results from Shionogi's EndeavorRx ADHD trialFebruary 27, 2024 | finance.yahoo.comPureTech to Present at Two Upcoming Investor ConferencesFebruary 27, 2024 | businesswire.comPureTech to Present at Two Upcoming Investor ConferencesFebruary 27, 2024 | finance.yahoo.comPureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in JapanFebruary 27, 2024 | businesswire.comPureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in JapanFebruary 22, 2024 | finance.yahoo.comPureTech Health plc (PRTC)February 15, 2024 | finance.yahoo.comDown -8.13% in 4 Weeks, Here's Why PureTech Health PLC Sponsored ADR (PRTC) Looks Ripe for a TurnaroundFebruary 9, 2024 | fool.co.ukLSE:PRTC (PureTech Health plc)January 23, 2024 | seekingalpha.comPRTC PureTech Health plcDecember 20, 2023 | msn.comPureTech outlook for 2024See More Headlines Receive PRTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PureTech Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/23/2024Next Earnings (Estimated)7/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:PRTC CUSIPN/A CIK1782999 Webwww.puretechhealth.com Phone617-482-2333Fax617-482-3337Employees90Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.76 Quick Ratio6.76 Sales & Book Value Annual Sales$750,000.00 Price / Sales1,063.61 Cash FlowN/A Price / Cash FlowN/A Book Value$16.94 per share Price / Book1.74Miscellaneous Outstanding Shares27,041,000Free Float25,608,000Market Cap$797.71 million OptionableNot Optionable Beta1.21 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Bharatt M. Chowrira J.D. (Age 59)Ph.D., CEO & Executive Director Comp: $2.19MMs. Daphne Zohar (Age 53)Founder, Senior Advisor & Board Observer Comp: $3.99MDr. Robert S. Langer Jr. (Age 75)Ph.D., Co-Founder & Non-Executive Director Comp: $135kDr. Eric Elenko Ph.D. (Age 51)President Dr. David R. Elmaleh Ph.D. (Age 76)Co-Founder & Senior Advisor Mr. Eric Green M.B.A.Chief Operating OfficerMs. Allison Mead TalbotHead of Communications & Investor RelationsMr. Charles Sherwood IIIJ.D., Ph.D., General Counsel & Company SecretaryMr. Spencer BallSenior Vice President of Human ResourcesMs. Aleksandra Filipovic M.D.Ph.D., Head of OncologyMore ExecutivesKey CompetitorsAurinia PharmaceuticalsNASDAQ:AUPHLongboard PharmaceuticalsNASDAQ:LBPHArcturus TherapeuticsNASDAQ:ARCTNurix TherapeuticsNASDAQ:NRIXImmunomeNASDAQ:IMNMView All CompetitorsInstitutional OwnershipAWM Investment Company Inc.Bought 6,900 shares on 5/16/2024Ownership: 0.026%View All Institutional Transactions PRTC Stock Analysis - Frequently Asked Questions How have PRTC shares performed in 2024? PureTech Health's stock was trading at $28.18 at the beginning of 2024. Since then, PRTC shares have increased by 4.7% and is now trading at $29.50. View the best growth stocks for 2024 here. When is PureTech Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024. View our PRTC earnings forecast. Who are PureTech Health's major shareholders? PureTech Health's stock is owned by a variety of institutional and retail investors. Top institutional investors include AWM Investment Company Inc. (0.03%). How do I buy shares of PureTech Health? Shares of PRTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRTC) was last updated on 5/23/2024 by MarketBeat.com Staff From Our PartnersBitcoin’s Biggest Year YetParadigm PressDividend-like income from non-dividend stocksUnstoppable ProsperityMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceThis could mean the end of the U.S dollar…Colonial MetalsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersGold Set to EXPLODE!Gold Safe Exchange[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaWrite this ticker symbol down…StocksToTrade Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PureTech Health plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
